Apalutamide and Nimodipine: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A induction may substantially reduce nimodipine exposure and efficacy.
Clinical significance and safety
Apalutamide and Nimodipine: The reviewed label generally advises avoiding strong CYP3A inducers. The treating teams should review alternatives and clinical response. Induction may persist after an inducing medicine stops; do not compensate by independently changing nimodipine.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.